

Thursday 4 September			
8.15–9.15	Registration and coffee		
9.15–12.00	<p>Conference room: High 1</p> <p>Opening Session</p> <p>Chair: Jon Thorkell Einarsson and Martina Frodlund (Sweden)</p> <p>Intro, Welcome to Malmö. Jon Thorkell Einarsson (Sweden)</p> <p>Awards from SRRF. Espen A. Haavardsholm (Norway), Eline Lundgaard (Norway)</p> <p>Industry-sponsored awards. Jon Thorkell Einarsson and Martina Frodlund (Sweden)</p> <p>What's New in RA? Speaker: Espen A. Haavardsholm (Norway)</p> <p>What's new in GCA? Speaker: Aladdin Mohammad (Sweden)</p> <p>What's new in SLE? Speaker: Anne Trolldborg (Denmark)</p>		
12.15–13.15	Lunch / Industry sponsored session in Conference room High 1		
	Conference room: High 1	Conference room: Live 1+2	Conference room: Live 3
13.15–14.30	<p>Understanding infection risk in rheumatic diseases</p> <p>Chairs: Laura Kuusalo (Finland) och Meliha Kapetanovic (Sweden)</p> <p>Speakers:</p> <p>Screening and prophylaxis for infections in patients with rheumatic diseases Kimme Hyrich (UK)</p> <p>Infection Risk in Inflammatory Arthritis: Focus on TNFi Therapy Aron Björnsson (Sweden/Iceland)</p> <p>Herpes zoster vaccination in patients with rheumatoid arthritis receiving JAK inhibitors Hanna Källmark (Sweden)</p>	<p>An Update on Renal involvement and new therapies in ANCA associated vasculitis</p> <p>Chairs: Aladdin Mohammad (Sweden) and Johanna Dahlqvist (Sweden)</p> <p>Speakers:</p> <p>New insights into diagnosis and predictive factors in ANCA glomerulonephritis Silke Brix (UK)</p> <p>New Therapies in ANCA associated vasculitis Rona Smith (UK)</p> <p>Abstracts</p> <p>Hanna Lindberg et al. Cardiovascular disease in patients with ANCA-associated vasculitides – a nationwide registry-based study from Sweden; 9450-A-2515</p>	<p>Immunopathology of Rheumatoid Arthritis</p> <p>Chairs: Silje Syversen (Norway) and Alf Kastbom (Sweden)</p> <p>Speaker:</p> <p>Utility of synovial biopsies for guiding treatment of rheumatoid arthritis Felice Rivellese (UK)</p> <p>Abstracts</p> <p>Sundbeck et al. A distinct pattern of T-cell and B-cell subpopulations predicts response to CTLA-4 Ig treatment in early rheumatoid arthritis; 9366-A-2515</p> <p>Cristina Maglio et al. Acylcarnitine Enrichment as A Characteristic of Rheumatoid Arthritis Fibroblast-Like Synoviocyte Metabolic Fingerprint; 9338-A-2515</p>
14.30–15.00	Coffee		
15.00–16.15	<p>Beyond B-cell depletion - novel therapies in systemic diseases</p> <p>Chairs: Francesca Faustini (Sweden) and Aikaterini Chatzidionysios (Sweden)</p> <p>Speakers:</p> <p>The evolution of B-cell directed therapies: from monoclonal antibodies to cell-based approaches Chris Wincup (UK)</p> <p>CAR-T treatment in autoimmune diseases: current evidences and future perspectives Melanie Hagen (Germany)</p> <p>Abstracts</p>	<p>ILD in the context of rheumatic disorders</p> <p>Chairs: Torkell Ellingsen (Denmark) and Anna-Karin Hultgård-Ekwall (Sweden)</p> <p>Speakers:</p> <p>Respiratory involvement in Rheumatic and CTDs: assesement of drug causality Philippe Camus (France)</p> <p>Treatment of RA associated interstitial lung disease Carl Turesson (Sweden)</p> <p>Abstract</p> <p>Hultgård Ekwall et al. Plasma levels of interferon-alpha are associated with the presence of radiographic airway</p>	<p>Imaging in axial spondylarthritis</p> <p>Chairs: Thorvardur Jon Löve (Iceland) and Tor Olofsson (Sweden)</p> <p>Speakers:</p> <p>Developments in imaging in axial spondyloarthritis Mikkel Østergaard (Denmark)</p> <p>Optimal use of imaging in the management of axial spondyloarthritis Sofia Ramiro (Netherlands)</p> <p>Abstract</p> <p>Johan K Wallman et al. Persistence of gut inflammation in axial spondyloarthritis associated with worse deterioration in spinal mobility over six years – Results from the SPARTAKUS cohort; 9292-A-2515</p>

	Albin Björk et al. Amlexanox inhibits production of type I interferon and suppresses B cell differentiation in vitro: a potential novel therapeutic option for SLE and other systemic inflammatory diseases; 9360-A-2515 Cecilia Fugmann et al. A high polygenic risk score is associated with multiple disease manifestations and MALT lymphoma in Sjögren's disease; 9398-A-2515	abnormalities in early untreated rheumatoid arthritis; 9440-A-2515	
16.15-16.35	Sponsor presentations Chair: Martina Frodlund		
16.35–	NETWORKING in the exhibition area		

Friday 5 September

	Run for Arthritis		
8.15–9.00	Industry sponsored session with breakfast in Conference room High 1		
	Conference room: High 1	Conference room: Live 1+2	Conference room: Live 3
9.10-10.25	<p>Gout, joint and beyond Chair: Lennart Jacobsson (Sweden)</p> <p>Speakers: Gout, cardiovascular risk and the role for SGLT1 Abhishek Abhishek (UK)</p> <p>Management of gout - lessons from the NOR-Gout study Tillman Uhlig (Norway)</p> <p>Gout in the Nordic countries Mats Dehlin (Sweden)</p>	<p>Disease mechanisms and treatment in idiopathic inflammatory myopathies Chairs: Antonella Notarnicola (Sweden) and Helene Alexandersson (Sweden)</p> <p>Speakers: Mechanisms of muscle weakness in inflammatory myopathy Daniel Andersson (Sweden)</p> <p>Exercise as treatment in idiopathic inflammatory myopathies Kristofer M Andreasson (Sweden)</p> <p>Abstracts Angeles S Galindo et al. Advancing Care in Necrotizing Myopathies: Rethinking High-Dose Glucocorticoids for Improved Outcomes in Anti-HMGCR+ Patients; 9370-A-2515</p> <p>Milica Vranic et al. Identification of differentially expressed genes in patients with Sjögren's disease and incident lymphomas; 9369-A-2515</p>	<p>Inspiring patient and public involvement in research Chair: Monica Persson (Sweden)</p> <p>Inspiring patient and public involvement in research</p> <p>Speakers: Earlier and later learning across my 30+ years of championing patient and public involvement in research Hywel Williams (UK)</p> <p>Developing core outcome sets for SLE in partnership with patients (OMERACT SLE) Ioannis Parodis (Sweden) and Yvonne Enman (Sweden)</p> <p>Being a patient partner in basic research Eva Johansson (Patient Partners, Sweden)</p> <p>Abstract Astrid Jensen Damgaard. Involvement of Patients and Relatives in the Development of a Combined Fatigue Intervention (COMFI) for People with Inflammatory Arthritis; 9383-A-2515</p>
10.25-10.45	Coffee		
10.45–12.00	<p>Comorbidities in Rheumatoid Arthritis Chairs: Dalia Miltiniene (Lithuania) and Lotta Ljung (Sweden)</p>	<p>SLE sub-phenotyping Are all the same? Chairs: Gerdur Gröndal (Iceland) and Karoline Lerang (Norway)</p>	<p>Physical Capacity in RMDs – assessment and exercise for individually tailored care Chairs: Tanja Thomsen (Denmark) and Monica Holmner (Sweden)</p>

	<p>Speakers: Cardiovascular risk management in patients with RA Anna Södergren (Sweden)</p> <p>Malignancy in patients with rheumatoid arthritis - clinical implications from register studies Johan Askling (Sweden)</p> <p>Osteoporosis in patients with RA Glenn Haugeberg (Norway)</p>	<p>Speakers: SLE: From Classification Criteria to Clinical Clusters I Henrik Leffers (Denmark) SLE: From Classification Criteria to Clinical Clusters II Elisabeth Svenungsson (Sweden)</p> <p>Abstracts Isak Samuelsson et al. Association between systemic lupus erythematosus and myocardial infarction subtypes – a matched cohort study in Sweden; 9305-A-2515</p> <p>Majd Bairkdar et al. Risk of ischemic and non-ischemic heart failure in patients with systemic sclerosis: a population-based study; 9346-A-2515</p>	<p>Speakers: Kasper Yde Jensen (Denmark) Kristine Røren Norden (Norway)</p> <p>Applying VO2peak testing in early myositis Kristofer M Andreasson (Sweden)</p> <p>Annelie Bilberg (Sweden)</p> <p>Abstract: Kasper Yde Jensen Sustained benefits of high-intensity resistance training in myositis, 9429-A-2515.</p>
12.15-13.15	Lunch / Industry sponsored session in Conference room High 1		
13.15-14.30	<p>Recent developments in the treatment of psoriatic arthritis Chairs: Sandra Meisalu (Estonia) and Johan Karlsson Wallman (Sweden)</p> <p>Speaker: Recent developments in the treatment of psoriatic arthritis Laure Gossec (France)</p> <p>Abstracts Vladimirova et al. Sacroiliac joint involvement in psoriatic arthritis –MRI, radiographic and clinical findings in 581 European real-world patients; 9295-A-2515</p> <p>Kjørholt et al. Clinical characteristics associated with achievement of sustainable drug-free remission in rheumatoid arthritis patients; 9458-A-2515</p>	<p>Complement in rheumatology and APS syndrome Chairs: Saedis Saeverdottir (Sweden) and Anne Trolldberg (Denmark)</p> <p>Speakers: Complement in Rheumatology: A Pathogenic Pathway and a Therapeutic Target Anna Blom (Sweden),</p> <p>Targeting the complement system in antiphospholipid syndrome Aleksandra Antovic (Sweden)</p> <p>Abstract Laila A Alharb et al. The Epidemiology of Primary Antiphospholipid syndrome in Southern Sweden; 9441-A-2515</p>	<p>Psychological well-being in RMD care Chairs: Malin Regardt (Sweden) and Yvonne Enman (Sweden)</p> <p>Speakers: To set the scene Bente Appel Esbensen (Denmark)</p> <p>The big challenge: living with an RMD and experiencing cognitive dysfunction Ingrid de Groot (Netherlands)</p> <p>Beyond the joints: Loneliness and its associations with disease activity and impact in inflammatory arthritis Annette De Thurah (Denmark)</p> <p>Self-management of inflammatory arthritis from the perspective of psychological well-being Luise Holberg Lindgren (Denmark)</p> <p>Abstracts Maria Andersson et al. How do empowerment and lifestyle influence fear-avoidance in patients with long-term RA?; 9330-A-2515</p> <p>Charlotte Sylwander et al. Knowing the Pain, Embracing Pain, and Building Resilience: Patients' Experiences of a Multimodal Rehabilitation Program for Chronic Pain; 9406-A-2515</p>
14.30-16.00	POSTER EXIBITION		
16.00–16.50	Polymyalgia Rheumatica: Beyond the Pain	Rare diseases in rheumatology and IgG4 syndrome: 2025 Kåre	Practical Strategies for Person-Centered Rheumatology

	<p>Chair: Aladdin Mohammad (Sweden)</p> <p>Speaker: Patient reported outcomes in polymyalgia rheumatica Sarah Mackie (UK)</p> <p>Abstract Fors et al. Predictors of developing Polymyalgia Rheumatica: a nested case-control study based on a population survey; 9109-A-2515</p>	<p>Berglund lecture</p> <p>Chair: Anders Bengtsson (Sweden)</p> <p>Speakers: IgG4-related disease: a 20 years journey Emanuell Della Torre (Italy)</p> <p>When to suspect an autoinflammatory disease and what to do Kari Eklund (Finland)</p>	<p>Chair: Ellen Landgren (Sweden)</p> <p>Speaker: Supporting Person-Centred Leadership across a hospital in Denmark Bibi Hølge-Hazelton (Denmark),</p> <p>Abstract: Ellen Landgren et al. Fostering a sense of security in early RA care through a very tight control clinic – A qualitative study; 9409-A-2515</p> <p>Expert panel for discussions Susanne Pettersson (Sweden) RN, Associate professor Sigrid Ødegaard (Norway) MD, PhD Jette Primdahl (Denmark) professor</p>
19.00-	Conference dinner (<i>registration is mandatory</i>)		

Saturday 6 September

	Conference room: High 1	Conference room: Live 1+2
8.15–9.00	Industry sponsored session with breakfast in Conference room High 1	
9.30–10.45	<p>Disease mechanisms and treatment in the very early phase of RA Chairs: Solbritt Rantapää-Dahlqvist (Sweden) and Per-Johan Jakobsson (Sweden)</p> <p>Speakers: Experience from treatment of ACPA positive inflammatory arthralgia Andrew P Cope (UK)</p> <p>Mucosal adaptive immunity in the prearthritis phase of RA Alf Kastbom (Sweden)</p> <p>Abstract Bäcklund et al. Diet and the risk of developing rheumatoid arthritis – assessment of dose-response relations based on a nested case-control study; 9448-A-2515</p>	<p>Biomarker discovery in systemic rheumatic diseases Chairs: Martina Frodlund (Sweden) and Henrik Leffers (Denmark)</p> <p>Speakers: The omics approach to unmet needs in rheumatic diseases Sædís Sævarsdóttir (Iceland)</p> <p>Inherited Susceptibility: The Genetic Puzzle of Systemic Rheumatic Diseases Dag Leonard (Sweden)</p> <p>Abstracts Amin Ravaei et al. Metabolomic and transcriptomic alterations in systemic sclerosis skin — a Western Sweden Systemic Sclerosis Project study; 9349-A-2515</p> <p>Albin Björk et al. A proteomic profile mirrors the salivary gland focus score and disease - associated antibodies in Sjögren's disease 9361-A-2515</p>
10.45–11.15	Coffee	
11.15–12.00	<p>Treatment and cardiovascular risk in RA Chair: Carl Turesson (Sweden)</p> <p>Speaker: Treatment and cardiovascular risk in RA: Anti-rheumatic treatment and cardiovascular risk in patients with rheumatoid arthritis Jon Giles (USA)</p> <p>Abstract Peltonen et al. ERA-CVD study: Subclinical coronary artery disease in patients with new-onset rheumatoid arthritis; 9421-A-2515</p>	
12.00–12.05	<p>Handing over the baton: Introducing the venue for the next SCR congress in 2027 Speaker: Jon Thorkell Einarsson (Sweden)</p>	
12.05–	GRAB AND GO (some macronutrients for the journey home)	